Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has shared an announcement.
Jiangsu Hengrui Pharmaceuticals has entered into a significant collaboration agreement with GlaxoSmithKline (GSK) to grant GSK exclusive worldwide rights, excluding certain regions, for HRS-9821, a PDE3/4 inhibitor in development for chronic obstructive pulmonary disease (COPD). This agreement also includes options for GSK to obtain licenses for up to 11 additional programs, potentially enhancing Hengrui’s global presence and impact in the pharmaceutical industry.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$134.00 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, focusing on the development and production of innovative drugs. The company is involved in the pharmaceutical industry, primarily offering products and services related to drug development and manufacturing, with a market focus on both domestic and international markets.
Average Trading Volume: 5,720,546
Current Market Cap: HK$409.1B
For detailed information about 1276 stock, go to TipRanks’ Stock Analysis page.